MAPT and Alzheimer disease: Interestingly, some studies found that a significant proportion of LGI1-Ab patients had either a CSF profile compatible with AD [22] or abnormalities in at least one core AD biomarker among total and phosphorylated tau (p-tau), and amyloid beta (Aβ)1–42 [68].